Meeting
2018 ASCO Annual Meeting
Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.
Authors
Samuel Martel
Centre Hospitalier Universitaire Sherbrook - Hopital Fleurimont, Sherbrooke, QC, Canada
Samuel Martel , Matteo Lambertini , Dominique Agbor-Tarh , Noam Falbel Ponde , Andrea Gombos , Vicki Paterson , Florentine Hilbers , Larissa Korde , Anna Manukyants , Amylou C. Dueck , Christian Maurer , Martine J. Piccart-Gebhart , Alvaro Moreno-Aspitia , Christine Desmedt , Serena Di Cosimo , Evandro De Azambuja
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Late and Long-Term Effects
Clinical Trial Registration Number
NCT00490139
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10067)
DOI
10.1200/JCO.2018.36.15_suppl.10067
Abstract #
10067
Poster Bd #
55
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Predictor of trastuzumab-induced cardiotoxicity in breast cancer (BC) patients: HER2/neu 655 polymorphisms, biochemical and clinical features.
First Author: Isabel Blancas
Poster
2021 ASCO Annual Meeting
A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study).
First Author: Tomomi Fujisawa
Poster
2020 ASCO Virtual Scientific Program
Geographic and demographic disparities in breast cancer outcomes: A population-based study.
First Author: Rohit Gosain
Poster
2016 ASCO Annual Meeting
Improved outcomes in stage I HER2 positive breast cancer patients treated with trastuzumab and chemotherapy.
First Author: Shruti Rakesh Tiwari